ArticleNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2024
The orexin neurotransmitter system as a target for medication development for opioid use disorder.
Article in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.
- Objective and subjective measurement of sleep in people who use substances: Emerging evidence and recommendations from a systematic review.Journal of sleep research · 2025Pooled it
- Effects of suvorexant on diurnal cortisol and patient-reported stress during opioid withdrawal in a randomized trial.Psychoneuroendocrinology · 2025Trial
- Hypothalamic Glutamatergic/Orexinergic Neurons Attenuate Fentanyl-Induced Respiratory Depression via Medullary Pre-BöTzinger Complex Pathways.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2026Article
- Found in translation: orexin receptor antagonism for the treatment of opioid use disorder.Translational psychiatry · 2025Review
- A Preliminary Report on the Effects of Daridorexant in Patients with Comorbid Insomnia and Substance Use Disorders.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Chronic Pain and Substance Use Disorders: A Brief Narrative Review of Genetic, Neurobiological, and Environmental Contributions to Comorbidity.Journal of psychiatry and brain science · 2025Article
- Associations Among Sleep, Pain, and Medications for Opioid Use Disorder: a Scoping Review.Current addiction reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.